B of A Securities Upgrades Apellis Pharmaceuticals to Buy, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad has upgraded Apellis Pharmaceuticals (NASDAQ:APLS) from Neutral to Buy and increased the price target from $52 to $85, indicating a positive outlook on the company's stock.

December 05, 2023 | 9:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has been upgraded by B of A Securities from Neutral to Buy, with a significant increase in price target from $52 to $85, suggesting a bullish stance on the stock.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved fundamentals or future prospects for the company. The substantial raise in the price target from $52 to $85 by B of A Securities reflects a strong conviction in Apellis Pharmaceuticals' potential for growth and profitability, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100